SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

Evolus, Inc. (EOLS) News

Follow Evolus, Inc. (EOLS) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 9 public stories across 8 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol EOLS Asset equity Sector Markets 90 days 6 Last 6.51 Updated Nov 05, 2026, 02:04 PM UTC Open live news feed Open EOLS chart & news
M Evolus Reports Q3 Revenue of $78 Million, Up 13% Evolus reported positive adjusted EBITDA for a fourth consecutive quarter and reaffirmed full-year revenue and margin guidance while lowering its operating expense guidance. EQUITY | Nov 05, 2026, 02:04 PM UTC M Evolus Reports Q3 Revenue Growth and Positive Adjusted EBITDA Evolus reported 13% year-over-year revenue growth and its fourth consecutive quarter of positive adjusted EBITDA. The company reaffirmed its full-year 2026 financial outlook. EQUITY | Nov 04, 2026, 09:09 PM UTC L Evolus Expands Pipeline With Injectable Hair Restoration Program Evolus announced a novel injectable hair restoration program. EQUITY | Oct 14, 2026, 12:40 PM UTC L Evolus CEO sold common shares worth over $950K Evolus President and CEO David Moatazedi reported a direct sale of common stock on 2026-09-02. The filing shows multiple trades priced $9.00 to $9.13, with a weighted average $9.0385 per share. EQUITY | Sep 04, 2026, 11:10 PM UTC L A Wave of Weight-Loss Drugs Is Quietly Creating a Multi-Billion-Dollar Opportunity That Aesthetic Medicine Is Racing to Capture NEW YORK, Sept. 1, 2026 /CNW/ -- Equity Insider News Commentary - The global medical aesthetics market has quietly become one of the most durable growth stories in healthcare. Multiple market-research firms size it at ro FX | Sep 01, 2026, 03:38 PM UTC L America Fell in Love With Filler. Then Came the Great Deflate — WSJ America Fell in Love With Filler. Then Came the Great Deflate — WSJ EQUITY | Aug 31, 2026, 06:40 PM UTC L EOLS - Evolus Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of Positive Adjusted EBITDA and Raise EOLS - Evolus Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of Positive Adjusted EBITDA and Raises Full-Year 2026 Financial Outlook EARNINGS | Aug 05, 2026, 08:16 PM UTC L Evolus Raises FY2026 Sales Guidance from $327.000M-$337.000M to $330.000M-$337.000M vs $330.445M Est Evolus (NASDAQ: EOLS ) raises FY2026 sales outlook from $327.000 million-$337.000 million to $330.000 million-$337.000 million vs $330.445 million estimate. EARNINGS | Aug 05, 2026, 08:09 PM UTC M Evolus Expands Partnership with Symatese Evolus expands partnership to commercialize Estyme EQUITY | Aug 04, 2026, 12:33 PM UTC